Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines
- PMID: 30223007
- DOI: 10.1016/j.gene.2018.09.027
Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines
Abstract
RON receptor tyrosine kinase is a transmembrane protein directly involved in suppression of inflammation and its aberrant expression linked to cancers and metastasis. Efforts to block deregulated RON signaling in tumors using small molecule kinase inhibitors or antibodies have been complicated by the presence of unknown number/types of isoforms of RON, which, despite being structurally similar, localize differently and mediate varied functions. Current study was designed to identify the splice variants of RON transcripts formed by skipping of sequences between exons 9 and 14 for better understanding of isoform specific RON signaling in cancers. PCR amplification and bi-directional sequencing of a 901 bp cDNA sequence located between exons 9 to 14 of RON from lung cancer cell lines revealed the presence of two splicing variants formed by skipping of exons 11 and 11-13. Each of these transcripts was found in more than one cell line. Expressed sequence tag (EST) database search indicated that the splicing variant lacking exons 11-13 was a novel one. Here we conclude that the splice variants of RON lacking exon 11 and exons 11-13 were detected in several lung cancer cell lines. Novel variant formed by skipping exons 11-13, the sequence of which code for transmembrane region, is predicted to code for a truncated isoform that may be secreted out. Tumors may antagonize the ligand dependent anti-inflammatory function of wild-type RON by secreting out the ligand binding isoforms.
Keywords: Alternative splicing; Lung cancer; Macrophage stimulating protein (MST1R); RON; RON isoform; Receptor tyrosine kinase.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.BMC Cancer. 2017 Nov 9;17(1):738. doi: 10.1186/s12885-017-3747-x. BMC Cancer. 2017. PMID: 29121914 Free PMC article.
-
Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.Lung Cancer. 2016 Feb;92:41-6. doi: 10.1016/j.lungcan.2015.12.002. Epub 2015 Dec 12. Lung Cancer. 2016. PMID: 26775595
-
Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.Int J Clin Exp Med. 2015 Nov 15;8(11):20778-86. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26885001 Free PMC article.
-
Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.Cancer Lett. 2007 Nov 18;257(2):157-64. doi: 10.1016/j.canlet.2007.08.007. Epub 2007 Sep 21. Cancer Lett. 2007. PMID: 17889431 Review.
-
RON, a tyrosine kinase receptor involved in tumor progression and metastasis.Ann Surg Oncol. 2005 Apr;12(4):273-81. doi: 10.1245/ASO.2005.08.013. Epub 2005 Mar 15. Ann Surg Oncol. 2005. PMID: 15827676 Review.
Cited by
-
Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.Ther Adv Med Oncol. 2020 May 12;12:1758835920920069. doi: 10.1177/1758835920920069. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32426050 Free PMC article. Review.
-
The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.Lab Invest. 2020 Dec;100(12):1589-1601. doi: 10.1038/s41374-020-0466-8. Epub 2020 Jul 15. Lab Invest. 2020. PMID: 32669614
-
Comprehensive analysis of DNA methylation and gene expression profiles in cholangiocarcinoma.Cancer Cell Int. 2019 Dec 26;19:352. doi: 10.1186/s12935-019-1080-y. eCollection 2019. Cancer Cell Int. 2019. PMID: 31889904 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials